While the injectable anti-VEGF monoclonal antibody bevacizumab is a well-established first-/second-line treatment option for advanced CRC [18,19], trials of oral, small molecule antiangiogenic agents have been largely unsuccessful in this setting. The gene discussed is VEGFA; the disease is colorectal carcinoma.